RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO) and raises the price target from $53 to $55.
August 02, 2024 | 7:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza maintains an Outperform rating on Agios Pharmaceuticals and raises the price target from $53 to $55.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively impact Agios Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100